Oramed Pharmaceuticals Inc. announced its unaudited financial results for the nine months ended September 30, 2025.
Key highlights include a significant increase in net income, full repayment from Scilex, and robust balance sheet growth.
The positive results were driven by cash returns from strategic investments and unrealized gains from equity holdings.
Net Income Surge
Net income (pre-tax) soared to $65.0 million compared to a net loss of $6.1 million in the same period last year.
Strategic Investment Payoff
Completed full repayment from Scilex, totaling $100 million, marking the full return of principal from the Company's strategic investment.
Per-Share Performance
Notable per-share performance with basic earnings per share of $1.30 and diluted earnings per share of $1.26.
- The company's disciplined investment strategy led to a remarkable increase in net income, demonstrating the effectiveness of their portfolio management.
- The full repayment from Scilex and substantial unrealized gains from equity holdings position Oramed with greater financial flexibility for future strategic endeavors.
Oramed's strong financial results are a testament to their successful investment strategy and operational performance, paving the way for future growth and innovation in oral drug delivery solutions.